H
Heron Therapeuti (HRTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$0.28
-0.03 (-8.44%)
Market Cap: $59.08M
Last updated: Nov 17, 2026 at 11:06 AM ET
Heron Therapeuti (HRTX) Valuation Multiples
Heron Therapeuti (HRTX) trades at 0.4x sales and 14.0x book value. Its P/S of 0.4x is below its 5-year median of 2.0x. Its forward P/E is 47.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 47.0x |
| Price to sales | 0.4x |
| Price to book | 14.0x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/S is 95.9% below 9.8x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 0.4x | 2.0x | 9.8x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 1.4x in 2025 to 402.3x in 2016. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $1.30 | 1.4x | 15.1x |
| 2024 | $1.53 | 1.6x | N/A |
| 2023 | $1.70 | 1.8x | N/A |
| 2022 | $2.50 | 2.5x | 21.9x |
| 2021 | $9.13 | 10.4x | 12.0x |
| 2020 | $21.17 | 21.7x | 8.2x |
| 2019 | $23.50 | 13.1x | 5.2x |
| 2018 | $25.94 | 24.9x | 5.5x |
| 2017 | $18.10 | 33.3x | 8.9x |
| 2016 | $13.10 | 402.3x | N/A |
Frequently Asked Questions About HRTX
What is HRTX's forward P/E ratio?
Heron Therapeuti has a forward P/E ratio of 47.0x.
What is HRTX's price to sales ratio?
Heron Therapeuti has a price to sales ratio of 0.4x.
HRTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors